Francesca Porcellati

Prof. Francesca Porcellati


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2011 in Diabetes Technology & Therapeutics
Verified
Journal Article
Open access
FPFrancesca Porcellati
Francesca Porcellati
GBGeremia B. Bolli
Geremia B. Bolli
CFCarmine Fanelli
Carmine Fanelli
The two basal insulin analogs, insulin glargine and insulin detemir, were developed to ameliorate the well-known limitations of NPH insulin. In contrast to rapid-acting analogs, which differ exclusively in terms of primary structure while sharing similar pharmacokinetics (PK) and pharmacodynamics (PD), the two long-acting insulin analogs are different chemical and structural entities, exhibiting distinct modes of protracting the insulin effect. So far, PK and PD studies of long-acting analogs have often shown conflicting results, pointing out different conclusions, thereby leading to animated controversies. The methods used in the evaluation of basal insulins might have been partially responsible as, although the euglycemic clamp technique has been broadly acknowledged to be the “gold standard” reference to assess the glucose-lowering effect of an insulin preparation, its execution and interpretation might have been substantially different across studies, in various methodological and analytical aspects, ultimately providing an explanation for some of these controversies. This review will present and describe the basic methods used in the evaluation of basal insulins and will critically summarize the points that might have been responsible for the different outcomes. The findings of glucose clamp studies demonstrate that the two long-acting insulin analogs are different, to some extent, in both their PK and PD profiles. These differences should be taken into consideration when the individual analogs are introduced to provide basal insulin supplementation to optimize blood glucose control in patients with type 1 and type 2 diabetes as well.

Verified
Journal Article
Open access
PDF file
AMAlessio Mazzieri
Alessio Mazzieri
FPFrancesca Porcellati
Francesca Porcellati
FTFrancesca Timio
Francesca Timio
GRGianpaolo Reboldi
Gianpaolo Reboldi
Diabetic kidney disease (DKD) is a chronic microvascular complication in patients with diabetes mellitus (DM) and the leading cause of end-stage kidney disease (ESKD). Although glomerulosclerosis, tubular injury and interstitial fibrosis are typical damages of DKD, the interplay of different processes (metabolic factors, oxidative stress, inflammatory pathway, fibrotic signaling, and hemodynamic mechanisms) appears to drive the onset and progression of DKD. A growing understanding of the pathogenetic mechanisms, and the development of new therapeutics, is opening the way for a new era of nephroprotection based on precision-medicine approaches. This review summarizes the therapeutic options linked to specific molecular mechanisms of DKD, including renin-angiotensin-aldosterone system blockers, SGLT2 inhibitors, mineralocorticoid receptor antagonists, glucagon-like peptide-1 receptor agonists, endothelin receptor antagonists, and aldosterone synthase inhibitors. In a new era of nephroprotection, these drugs, as pillars of personalized medicine, can improve renal outcomes and enhance the quality of life for individuals with DKD.

1 February 2017 in Medicine
Verified
Journal Article
Open access
PDF file
FPFrancesca Porcellati
Francesca Porcellati
JLJay Lin
Jay Lin
PLPaola Lucidi
Paola Lucidi
GBGeremia B. Bolli
Geremia B. Bolli
CFCarmine Fanelli
Carmine Fanelli
The goal of this post hoc analysis was to determine key patient and treatment-related factors impacting glycosylated hemoglobin (A1C) and hypoglycemia in patients with uncontrolled type 2 diabetes who were initiated to basal insulin (neutral protamine Hagedorn [NPH] or glargine). Using individual patient-level data pooled from 6 treat-to-target trials, 2600 patients with type 2 diabetes on oral antidiabetic agents initiated to insulin glargine or NPH and treated for 24 to 36 weeks were analyzed. Both treatments led to significant reduction in A1C levels compared with baseline, with no differences between treatment groups (mean ± standard deviation; glargine: −1.32 ± 1.2% vs NPH: −1.26 ± 1.2%; P = 0.15), with greater reduction in the BMI ≥30 kg/m2 group than in the BMI <30 kg/m2 group. Glargine reduced A1C significantly more than NPH in the BMI <30 kg/m2 group (−1.30 ± 1.18% vs −1.14 ± 1.22, respectively; P = 0.008), but not in the BMI ≥ 30 kg/m2 group (−1.37 ± 1.19 vs −1.48 ± 1.22, respectively; P = 0.18). Similar proportions of patients achieved A1C target of <7% (glargine 30.6%, NPH 29.1%; P = 0.39). Incidence of severe and severe nocturnal hypoglycemia was significantly lower in glargine versus NPH-treated patients (2.0% vs 3.9%; P = 0.04, and 0.7% vs 2.1%; P = 0.002, respectively), and occurred primarily in the BMI <30 kg/m2 group. Initiation of basal insulin is highly effective in lowering A1C after oral antidiabetic agent failure. Glargine decreases A1C more than NPH in nonobese patients, and reduces the risk for severe and severe nocturnal hypoglycemia versus NPH both in obese and nonobese patients, but more so in nonobese patients. Thus, it is the nonobese patients who may benefit more from initiation of basal insulin as glargine than NPH.

27 August 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
FPFrancesca Porcellati
Francesca Porcellati
SMStefania Di Mauro
Stefania Di Mauro
AMAlessio Mazzieri
Alessio Mazzieri
ASALESSANDRA SCAMPORRINO
ALESSANDRA SCAMPORRINO
AFAgnese Filippello
Agnese Filippello
Salvatore PiroSalvatore Piro
Salvatore Piro
Hypoglycemia represents a dark and tormented side of diabetes mellitus therapy. Patients treated with insulin or drug inducing hypoglycemia, consider hypoglycemia as a harmful element, which leads to their resistance and lack of acceptance of the pathology and relative therapies. Severe hypoglycemia, in itself, is a risk for patients and relatives. The possibility to have novel strategies and scientific knowledge concerning hypoglycemia could represent an enormous benefit. Novel available glucagon formulations, even now, allow clinicians to deal with hypoglycemia differently with respect to past years. Novel scientific evidence leads to advances concerning physiopathological mechanisms that regulated glycemic homeostasis. In this review, we will try to show some of the important aspects of this field.

2 April 2025 in Diabetes Research and Clinical Practice
Verified
Journal Article
Open access
MFMichelantonio De Fano
Michelantonio De Fano
AMAlessio Mazzieri
Alessio Mazzieri
CFCarmine G. Fanelli
Carmine G. Fanelli
FMFrancesca Mancinetti
Francesca Mancinetti
DXDionysios Xenos
Dionysios Xenos
FPFrancesca Porcellati
Francesca Porcellati
The STOP study is a proof-of-concept, aimed at evaluating the effectiveness and safety of IdegLira in deintensifying diabetes therapy in elderly insulin-treated persons with T2DM. The study was a real world, single center retrospective observation. 96 persons were enrolled (46F, age 77 ± 7 yrs, HbA1C 7.5 ± 1.0, diabetes duration 21 ± 10 yrs; 75 % in basal/bolus insulin therapy). After 6 months (T6), fasting plasma glucose significantly decreased as compared to T0, as did HbA1C. The switch to IdegLira was associated with significantly lower rates of level 1 (L1) hypoglycemia at T3 (IR 0.24, 95 % CI 0.11-0.58, p < 0.001) and T6 (IR 0.08, 95 % CI 0.02-0.34, p < 0.001) as compared to T0. Level 2 (L2) hypoglycemia rates significantly decreased at T3 (IR 0.04, 95 % CI 0.01-0.32, p < 0.001) as compared to T0. The proportion of persons (incidence) with L1 hypoglycemia decreased from 33.7 % at T0 to 17.4 % at T3 (p = 0.004) and to 5.8 % at T6 (p < 0.001). Incidence of L2 hypoglycemia decreased from 22.1 % at T0 to 1.16 % at T3 (p < 0.001). No patients had L2 hypoglycemia at T6. Rapid acting insulin was interrupted in 85 % of patients. IdegLira represents a viable option in deintensifying insulin therapy in an elderly population.

23 January 2019 in L'Endocrinologo
Verified
Journal Article
Closed access
PDF file
FPFrancesca Porcellati
Francesca Porcellati
PLPaola Lucidi
Paola Lucidi
GBGeremia B. Bolli
Geremia B. Bolli
CFCarmine G. Fanelli
Carmine G. Fanelli